drug

privosegtor

1 story · latest Sep 30, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Oculis

Timeline

Oculis board member Lionel Carnot resigns after nearly a decade

Sep 30PeopleOculis

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.